Escitalopram for the Treatment of Self-Injurious Skin Picking
NCT00115011 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2008-05-20
Summary
The purpose of this study is to determine the effectiveness of escitalopram in treating self-injurious skin picking.
Conditions
- Impulse Control Disorders
Interventions
- DRUG
-
Escitalopram
Sponsors & Collaborators
-
Forest Laboratories
collaborator INDUSTRY -
Massachusetts General Hospital
lead OTHER
Principal Investigators
-
Nancy J Keuthen, Ph.D. · Massachusetts General Hospital
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-09-30
- Completion
- 2005-11-30
Countries
- United States
Study Locations
More Related Trials
-
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
NCT00252330 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder
NCT00252343 ·Status: COMPLETED ·Phase: PHASE3
-
Escitalopram in the Treatment of Dysthymic Disorder, Double Blind
NCT00220701 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder
NCT00109044 ·Status: COMPLETED ·Phase: PHASE3
-
Brain Imaging and Treatment Studies of the Night Eating Syndrome
NCT01401595 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
NCT00252356 ·Status: COMPLETED ·Phase: PHASE3
-
Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients
NCT00384436 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111552 ·Status: TERMINATED ·Phase: PHASE3
-
Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder
NCT00149799 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression
NCT01814085 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111539 ·Status: TERMINATED ·Phase: PHASE3
-
A Naturalistic Study of the Efficacy and Safety of Escitalopram in Treatment Resistant Depression
NCT00220480 ·Status: UNKNOWN ·Phase: NA
-
Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
NCT01103180 ·Status: TERMINATED ·Phase: PHASE2
-
A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder
NCT02288325 ·Status: COMPLETED ·Phase: PHASE4
-
The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis
NCT00151294 ·Status: TERMINATED ·Phase: PHASE4
-
Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions
NCT01368432 ·Status: COMPLETED ·Phase: PHASE2
-
Tolerability and Efficacy of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder (OCD)
NCT00305500 ·Status: COMPLETED ·Phase: PHASE3
-
Neurobiological Bases of Placebo Response in Major Depressive Disorder
NCT01787240 ·Status: TERMINATED ·Phase: PHASE4
-
Escitalopram (Lexapro) for Depression MS or ALS
NCT00965497 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
NCT04599855 ·Status: COMPLETED ·Phase: PHASE4
-
The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder
NCT00107120 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111565 ·Status: TERMINATED ·Phase: PHASE3
-
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
NCT04829318 ·Status: COMPLETED ·Phase: PHASE4
-
Escitalopram as a Mood Stabilizer for Bipolar II Disorder
NCT00156325 ·Status: COMPLETED ·Phase: PHASE2
-
Escitalopram Treatment of Night Eating Syndrome
NCT00636649 ·Status: COMPLETED ·Phase: NA